Group 1 - Benchmark raised its price target on Live Nation Entertainment to $190 from $180 while maintaining a Buy rating, acknowledging potential regulatory delays until 2026 [1] - Ongoing scrutiny from Washington regulators includes the FTC pursuing legal action over secondary market ticket premiums, with Live Nation advocating for a 20% cap on secondary market markups [2] - Analysts believe Live Nation's strong growth profile and business-to-business focus could justify higher valuations if viewed in line with Nasdaq 100 companies rather than the S&P 500 [3]

Group 1 - Healthcare stocks in the U.S. are experiencing pressure due to increasing regulatory headwinds and rising costs [1]